PTC Therapeutics, Inc. Payment for Debt Extinguishment or Debt Prepayment Cost
PTC Therapeutics, Inc. (PTCT) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $81.93 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2026-02-19
- PTC Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2020-12-31 was $0.00.
- PTC Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $81.93M.
- PTC Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2020 was $597.00K.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|
| 2023-12-31 | $81.93M 10-K · filed 2026-02-19 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $597.00K 10-K · filed 2023-02-21 | |
| 2020-09-30 | $597.00K 10-Q · filed 2021-10-28 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |